Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166669 | 0.81 | ALDH1A1 (0.34) | TSHRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4161304 | 0.78 | PDE10A (0.31) | — | |
| SCHEMBL4165752 | 0.77 | CRHR1 (0.32) | L3MBTL1 | |
| SCHEMBL4180510 | 0.74 | KDR (0.46) | TSHRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17628629 | 0.70 | SRC (0.34) | TSHRHTTKMT2ANPSR1 | |
| SCHEMBL4164259 | 0.69 | CRHR1 (0.33) | — | |
| SCHEMBL4166724 | 0.67 | EGFR (0.38) | TSHRL3MBTL1MAPT | |
| SCHEMBL6833888 | 0.66 | CRHR1 (0.45) | TSHRMAPK1L3MBTL1MAPTKMT2A | |
| SCHEMBL4171837 | 0.64 | HDAC1 (0.36) | — | |
| SCHEMBL4172055 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | claimed |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2006-05-18 | — | — | US | claimed |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | PMP22, BDNF, GRIK5 | TSHR 3283/4885MAPK1 1042/4885CYP1A2 864/4885 |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | BDNF, NTRK2, NGF | TSHR 486/4885MAPK1 1073/4885CYP1A2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.